New studies evaluate the impact of age on overall survival in adolescents and young adults (AYAs) with chronic lymphocytic leukemia, as well as response rates of rituximab in 2 combination regimens for hairy-cell leukemia and follicular lymphoma.
Younger Age, Higher Mortality Risk Linked in CLL
Age impacts overall survival (OS) in adolescents and young adults with chronic lymphocytic leukemia (CLL), reported OncLive®.
The HR for OS when comparing patients younger than 30 years with patients 35 to 29 years was 1.72 (95% CI, 1.10-2.70), and when comparing patients younger than 30 years with patients aged 30 to 34 years, it was 2.33 (95% CI, 0.83-6.25).
Age was also associated with the time to developing Richter transformation, in which B-cell CLL transforms into a fast-growing diffuse large B-cell lymphoma. For patients younger than age 30, the probability of being free from Richter transformation 5 years after diagnosis was 86% compared with 92% for patients aged 30 to 34 years and 99% for patients aged 35 to 39 years.
Vemurafenib Combination Treatment Leads to Complete Response
Patients with relapsed or refractory hairy-cell leukemia (HCL) who were treated with vemurafenib plus rituximab had durable complete responses (CRs), according to Cancer Network®.
The phase 2 study enrolled 30 patients with HCL who had received a median of 3 prior therapies and examined the safety and efficacy of the chemotherapy-free, nonmyelotoxic regimen of vemurafenib in combination with rituximab. The primary end point was CR at the end of treatment.
The patients received 960 mg of vemurafenib twice daily for 8 weeks plus 375 mg per square meter of body-surface area of rituximab administered concurrently and sequentially for 8 doses over 18 weeks. The majority (86.6%) of patients experienced a CR, and in this group were 10 patients who were refractory to chemotherapy, 5 who were refractory to rituximab, and 7 patients previously treated with BRAF inhibitors.
Learn more about the study at Cancer Network®.
Partial, Complete Response Seen With Lutetium Lilotomab Satetraxetan
A small cohort of patients with follicular lymphoma treated with lutetium lilotomab satetraxetan plus rituximab in the second-line setting had a high rate of CR, according to preliminary data from a phase 1b study.
The Archer-1 trial is ongoing, and the researchers were able to review data on 7 patients. All of the patients had at least a partial response and 5 patients (71.4%) had a CR. Five of the total responses have lasted at least 2 years since administration of lutetium lilotomab satetraxetan.
“We are encouraged by the results in this small phase 1 study in second-line FL patients. Both the overall safety of this combination and the preliminary signs of efficacy are promising,” Peter Braun, Nordic Nanovector CEO, said in a press release. “We look at this study as an additional building block in our overall strategy to develop Betalutin for difficult to treat hematological tumors. Our near-term focus remains very much on completing PARADIGME in [third-line] FL and delivering top line 3-month data by the end of 2021.”
Learn more the preliminary results at Cancer Network®.